Top

Published in:

01-02-2022 | Migraine | Original Article

Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache

Authors: Umberto Pensato, Carlo Baraldi, Valentina Favoni, Maria Michela Cainazzo, Paola Torelli, Pietro Querzani, Alessia Pascazio, Davide Mascarella, Eleonora Matteo, Simone Quintana, Gian Maria Asioli, Pietro Cortelli, Giulia Pierangeli, Simona Guerzoni, Sabina Cevoli

Published in: Neurological Sciences | Issue 2/2022

Abstract

Objective

To determine whether erenumab is effective and safe in refractory chronic migraine with medication overuse headache.

Methods

In this prospective, multicentric, real-life study, chronic migraine with medication overuse headache patients who received erenumab were recruited. Study inclusion was limited to patients who previously failed onabotulinumtoxinA in addition to at least three other pharmacological commonly used migraine preventive medication classes.

Results

Of 396 patients who received erenumab, 38% (n = 149) met inclusion criteria. After 3 months, 51% (n = 76) and 20% (n = 30) patients achieved ≥ 50% and ≥ 75% reduction in monthly headache days, respectively. Monthly pain medications intake decreased from 46.1 ± 35.3 to 16.8 ± 13.9 (p < 0.001), while monthly headache days decreased from 25.4 ± 5.4 to 14.1 ± 8.6 (p < 0.001). Increasing efficacy of erenumab over the study period was observed. Allodynia was a negative predictive factor of erenumab response (odds ratio = 0.47; p = 0.03). Clinical conversion to episodic migraine with no medication overuse was observed in 64% (n = 96) patients. No serious adverse events were observed.

Conclusions

Erenumab reduced significantly migraine frequency and pain medication intake in refractory chronic migraine with MOH patients.

Natoli JL, Manack A, Dean B et al (2010) Global prevalence of chronic migraine: a systematic review. Cephalalgia 30:599–609CrossRef

Munksgaard SB, Jensen RH (2014) Medication overuse headache. Headache 54:1251–1257CrossRef

Lanteri-Minet M, Duru G, Mudge M, Cottrell S (2011) Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia 31:837–850CrossRef

D’Amico D, Leone M, Grazzi L, Bussone G (2008) When should “chronic migraine” patients be considered “refractory” to pharmacological prophylaxis? Neurol Sci 29(Suppl 1):S55–S58CrossRef

Schulman EA, Brahin EJ (2008) Refractory headache: historical perspective, need, and purposes for an operational definition. Headache 48:770–777CrossRef

Schulman EA, Lake AE 3rd, Goadsby PJ et al (2008) Defining refractory migraine and refractory chronic migraine: proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society. Headache 48:778–782CrossRef

Sacco S, Braschinsky M, Ducros A et al (2020) European headache federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain 21:76CrossRef

(2018) Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1–211

Urits I, Jones MR, Gress K et al (2019) CGRP antagonists for the treatment of chronic migraines: a comprehensive review. Curr Pain Headache Rep 23:29CrossRef

10.

Tepper S, Ashina M, Reuter U et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16:425–434CrossRef

11.

Goadsby PJ, Reuter U, Hallstrom Y et al (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377:2123–2132CrossRef

12.

Barbanti P, Aurilia C, Egeo G, Fofi L, Cevoli S, Colombo B, Filippi M, Frediani F, Bono F, Grazzi L, Salerno A, Mercuri B, Carnevale A, Altamura C, Vernieri F (2021) Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in real life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache 61(2):363–372. https://doi.org/10.1111/head.14032

13.

Tepper SJ (2019) CGRP and headache: a brief review. Neurol Sci 40:99–105CrossRef

14.

Matteo E, Favoni V, Pascazio A, Pensato U, Benini M, Asioli GM, Merli E, Calabrò C, Cortelli P, Pierangeli G, Cevoli S (2020) Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna headache center. Neurol Sci 41(2):483–484. https://doi.org/10.1007/s10072-020-04667-0

15.

Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21:61CrossRef

16.

Ornello R, Casalena A, Frattale I et al (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain 21:32CrossRef

17.

Curone M, Tullo V, Bussone G (2020) Effectiveness of erenumab in chronic migraine patients with associated medication overuse headache: a prospective observational study. Neurol Sci 41:509–510CrossRef

18.

Scheffler A, Messel O, Wurthmann S et al (2020) Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain 21:84CrossRef

19.

Cainazzo MM, Baraldi C, Ferrari A, Lo Castro F, Pani L, Guerzoni S (2021) Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study. Neurol Sci. https://doi.org/10.1007/s10072-021-05105-5

20.

Shin HE, Park JW, Kim YI, Lee KS (2008) Headache Impact Test-6 (HIT-6) scores for migraine patients: Their relation to disability as measured from a headache diary. J Clin Neurol 4:158–163CrossRef

21.

Sarchielli P, Pini LA, Zanchin G et al (2006) Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders. Cephalalgia 26:257–265CrossRef

22.

Bendtsen L, Sacco S, Ashina M et al (2018) Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain 19:91CrossRef

23.

Ornello R, Tiseo C, Frattale I et al (2019) The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal. J Headache Pain 20:99CrossRef

24.

Dodick DW, Ashina M, Brandes JL et al (2018) ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38:1026–1037CrossRef

25.

Reuter U, Goadsby PJ, Lanteri-Minet M et al (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392:2280–2287CrossRef

26.

Raffaelli B, Kalantzis R, Mecklenburg J et al (2020) Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxinA: a dual-center retrospective observational study. Front Neurol 11:417CrossRef

27.

Pensato U, Favoni V, Pascazio A, Benini M, Asioli GM, Merli E, Calabrò C, Cortelli P, Pierangeli G, Cevoli S (2020) Erenumab efficacy in highly resistant chronic migraine: a real-life study. Neurol Sci 41(2):457–459. https://doi.org/10.1007/s10072-020-04658-1

28.

Russo A, Silvestro M, Scotto di Clemente F et al (2020) Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain 21:69CrossRef

29.

Pellesi L, Do TP, Ashina H, Ashina M, Burstein R (2020) Dual therapy with anti-CGRP monoclonal antibodies and botulinum toxin for migraine prevention: is there a rationale? Headache 60:1056–1065CrossRef

30.

Tepper SJ, Diener HC, Ashina M et al (2019) Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology 92:e2309–e2320CrossRef

31.

Sacco S, Bendtsen L, Ashina M et al (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20:6CrossRef

32.

Lipton RB, Burstein R, Buse DC, Dodick DW, Koukakis R, Klatt J, Cheng S, Chou DE (2021) Efficacy of erenumab in chronic migraine patients with and without ictal allodynia. Cephalalgia 3331024211010305. https://doi.org/10.1177/03331024211010305

33.

Ashkenazi A, Sholtzow M, Shaw JW, Burstein R, Young WB (2007) Identifying cutaneous allodynia in chronic migraine using a practical clinical method. Cephalalgia 27:111–117CrossRef

34.

Seo JG, Park SP (2019) Clinical significance of sensory hypersensitivities in migraine patients: does allodynia have a priority on it? Neurol Sci 40:393–398CrossRef

35.

Lovati C, Giani L, Mele F et al (2016) Brain plasticity and migraine transformation: fMRI evidences. Expert Rev Neurother 16:1413–1425CrossRef

36.

Barbanti P, Aurilia C, Egeo G, Fofi L (2019) Erenumab: from scientific evidence to clinical practice-the first Italian real-life data. Neurol Sci 40:177–179CrossRef

37.

Schwedt TJ (2018) Preventive therapy of migraine Continuum (Minneap Minn) 24:1052–1065

38.

Deen M, Correnti E, Kamm K et al (2017) Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain 18:96CrossRef

39.

Ashina M, Goadsby PJ, Reuter U et al (2019) Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia 39:1455–1464CrossRef

Title: Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache
Authors: Umberto Pensato
Carlo Baraldi
Valentina Favoni
Maria Michela Cainazzo
Paola Torelli
Pietro Querzani
Alessia Pascazio
Davide Mascarella
Eleonora Matteo
Simone Quintana
Gian Maria Asioli
Pietro Cortelli
Giulia Pierangeli
Simona Guerzoni
Sabina Cevoli
Publication date: 01-02-2022
Publisher: Springer International Publishing
Keywords: Migraine
Medication Overuse Headache
Headache
Erenumab
Published in: Neurological Sciences / Issue 2/2022
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-021-05426-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache

Abstract

Objective

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2022

“Don’t know” sign: description and evaluation of its diagnostic accuracy for cognitive impairment

The practice of teleneurology in the Philippines during the COVID-19 pandemic

An immigrant family with Kii amyotrophic lateral sclerosis/parkinsonism–dementia complex

The effectiveness of cognitive-motor training on reconstructing cognitive health components in older male adults, recovered from the COVID-19

Down syndrome: the aggravation of COVID-19 may be partially justified by the expression of TMPRSS2

Psychological factors associated with headache frequency, intensity, and headache-related disability in migraine patients